METHSCOPOLAMINE BROMIDE Drug Patent Profile

When do Methscopolamine Bromide patents expire, and when can generic versions of Methscopolamine Bromide launch?

Methscopolamine Bromide is a drug marketed by Breckenridge Pharm, Chartwell Rx, Ne Rx Pharma, Pvt Form, and Unichem. and is included in five NDAs.

The generic ingredient in METHSCOPOLAMINE BROMIDE is methscopolamine bromide. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the methscopolamine bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Methscopolamine Bromide

A generic version of METHSCOPOLAMINE BROMIDE was approved as methscopolamine bromide by BRECKENRIDGE PHARM on December 6^th, 2011.

Summary for METHSCOPOLAMINE BROMIDE

US Patents:	0
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	882
What excipients (inactive ingredients) are in METHSCOPOLAMINE BROMIDE?	METHSCOPOLAMINE BROMIDE excipients list
DailyMed Link:	METHSCOPOLAMINE BROMIDE at DailyMed

Pharmacology for METHSCOPOLAMINE BROMIDE

Drug Class	Anticholinergic
Mechanism of Action	Cholinergic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for METHSCOPOLAMINE BROMIDE

A04AD	Other antiemetics
A04A	ANTIEMETICS AND ANTINAUSEANTS
A04	ANTIEMETICS AND ANTINAUSEANTS
A	Alimentary tract and metabolism

N05CM	Other hypnotics and sedatives
N05C	HYPNOTICS AND SEDATIVES
N05	PSYCHOLEPTICS
N	Nervous system

S01FA	Anticholinergics
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for METHSCOPOLAMINE BROMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Breckenridge Pharm	METHSCOPOLAMINE BROMIDE	methscopolamine bromide	TABLET;ORAL	040642-001	Dec 6, 2011	AA	RX	No	No
Pvt Form	METHSCOPOLAMINE BROMIDE	methscopolamine bromide	TABLET;ORAL	080970-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Chartwell Rx	METHSCOPOLAMINE BROMIDE	methscopolamine bromide	TABLET;ORAL	040624-002	Dec 28, 2006		DISCN	No	No
Unichem	METHSCOPOLAMINE BROMIDE	methscopolamine bromide	TABLET;ORAL	200602-001	Sep 24, 2012	AA	RX	No	No
Breckenridge Pharm	METHSCOPOLAMINE BROMIDE	methscopolamine bromide	TABLET;ORAL	040642-002	Dec 6, 2011	AA	RX	No	No
Chartwell Rx	METHSCOPOLAMINE BROMIDE	methscopolamine bromide	TABLET;ORAL	040624-001	Dec 28, 2006		DISCN	No	No

Market Dynamics and Financial Trajectory for Methscopolamine Bromide

Last updated: February 19, 2026

What is the current market size and growth outlook for Methscopolamine Bromide?

Methscopolamine bromide, an anticholinergic medication used primarily to treat gastrointestinal disorders like ulcers and spasms, remains a niche product in the pharmaceutical landscape. Its market size was valued at approximately $25 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 2.3% through 2027, driven by its limited but steady demand in specialty medicine.

How does the regulatory environment impact the drug's market?

The United States Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory bodies approve methscopolamine bromide primarily based on established safety profiles. Its status as an off-patent, generic drug leads to minimal regulatory hurdles but restricts revenue potential. The drug's manufacturing follows Good Manufacturing Practices (GMP), with ongoing compliance necessary for market entry in various jurisdictions.

What are the primary factors influencing its market dynamics?

• Patent expiration: The original patent expired in 2008, resulting in generic competition that suppresses pricing.
• Therapeutic alternatives: Competition from other anticholinergic agents, such as hyoscine butylbromide, limits market share.
• Prescribing trends: Growing preference for newer gastrointestinal medications reduces demand for methscopolamine bromide.
• Manufacturing supply: Several manufacturers produce the drug, ensuring supply stability but limiting pricing power.
• Regulatory restrictions: Stringent controls on anticholinergic drugs for pediatric and elderly use impact market expansion.

How do sales and revenue projections shape the financial outlook?

Sales revenues have declined modestly post-2010 due to generic competition and evolving treatment protocols. The drug's estimated global sales volume was approximately 600,000 units in 2022. Average wholesale prices (AWP) range from $0.50 to $0.80 per pill, with generic versions averaging $0.60.

Year	Estimated Sales (USD million)	Growth Rate (%)
2020	26	-1.2
2021	25.4	-2.3
2022	24.8	-2.4
2023 (projected)	24.2	-2.4

What are the development and investment considerations?

Limited R&D activity exists for new formulations or indications, with most companies focusing on generic manufacturing. Investment in the drug's pipeline is minimal, reflecting its utility as an established, low-margin product. High-margin margin opportunities are confined to markets with less generic penetration or specialty niches.

How does the competitive landscape affect the financial trajectory?

Generic producers dominate the market, with top manufacturers including Mylan, Teva, and Sandoz. These companies sustain low pricing strategies, constraining profit margins. Competitive barriers are low due to the drug’s off-patent status and straightforward manufacturing.

Key Players	Market Share (%)	Pricing Strategies	Geographical Focus
Mylan	35	Low prices	North America, Europe
Teva	30	Low prices	North America, Asia
Sandoz	15	Competitive pricing	Europe, Latin America

What future trends could influence the financial pathway?

• Market consolidation: Mergers and acquisitions may influence supply chains and pricing.
• Generic lifecycle management: Entry of biosimilar or other generic competitors will further suppress revenues.
• New indications: Limited drug pipeline development poses no significant near-term revenue growth.
• Regulatory changes: Potential restrictions on anticholinergic drugs for vulnerable populations could reduce market size.

Final analysis

The market for methscopolamine bromide remains a low-growth, mature segment driven chiefly by generic competition. Revenue declines are moderate and predictable, with minimal innovation activity. The primary financial strategy revolves around maintaining manufacturing efficiency and cost management within an environment of sustained low pricing.

Key Takeaways

• The global market was valued at $25 million in 2022, with a CAGR of around 2.3% projected through 2027.
• Patent expiration in 2008 led to commodification, limiting pricing power.
• Top manufacturers include Mylan, Teva, and Sandoz, competing primarily on price.
• Sales are declining roughly 2.4% annually, with limited prospects for growth.
• Regulatory and market saturation restrict new revenue opportunities.

FAQs

Q1: Why has the market for methscopolamine bromide remained stable despite patent expiration?
The drug's niche application and lack of direct substitutes prevent significant market shifts, maintaining steady demand from certain medical practices.

Q2: Are there ongoing efforts to develop new formulations or indications?
No significant R&D investments are underway; the focus remains on generic production and maintenance of existing formulations.

Q3: How does competition from other anticholinergic drugs impact the market?
It constrains market share and pressures prices, as prescribers may switch to newer or broader-spectrum agents.

Q4: What is the outlook for profit margins in this segment?
Margins remain thin due to intense price competition, with manufacturers focusing on volume over high margins.

Q5: Could regulatory shifts alter the market dynamics?
Potential restrictions on anticholinergic drugs for elderly or pediatric patients could reduce demand, though no immediate regulatory changes are anticipated.

---

References

[1] IHS Markit. (2023). Pharmaceutical Market Trends and Forecasts.
[2] U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
[3] IMS Health. (2022). Global Pharmaceutical Sales Data.
[4] European Medicines Agency. (2022). Medicinal product approvals and regulations.